New research shows bezlotoxumab is effective at reducing the risk of recurrent Clostridioides difficile infections (CDI) at the 90 day mark in a cohort of patients recently receiving solid-organ transplantation.
A team, led by Tanner M. Johnson, Department of Pharmacy, UCHealth University of Colorado Hospital, compared recurrent C difficile infection rates in solid-organ and hematopoietic-cell transplant recipients.
Read more, here.